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To better understand the associations between history of tobacco use and survival outcomes, cigarette use 
was prospectively surveyed in 687 previously untreated patients with cancer of the oral cavity (271), 
oropharynx (257), larynx (135) or hypopharynx (24).   
METHODS: 
Kaplan-Meier and Cox models explored associations of tobacco use intensity (packs/day), duration (years of 
use) and timing prior to diagnosis with overall and disease specific  survival and recurrence free time .   
RESULTS:  
Cigarette use duration, timing, and intensity were significant predictors for all outcomes in univariate analysis.  
Never smoking and pack years were not significantly associated with outcomes after adjustment for 
prognostic factors such as stage, comorbidities, and HPV status which were strongly associated with clinical 
outcomes.   
CONCLUSIONS: 
The findings confirm the association between smoking history and survival  and the importance of clinical 
variables in evaluating smoking as a prognostic factor.  Timing, intensity, and duration of cigarette use should 
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Approximately 35- 55% of patients with head and neck squamous cell carcinoma (HNSCC) experience 
locoregional recurrence or distant metastasis within two years of initial diagnosis (1, 2) and are at high risk for 
developing a second primary(3).  There are many established factors associated with higher rates of 
recurrence, including tumor site, stage, Human Papillomavirus status, and diet(4).  Patients with Human 
Papillomavirus positive (HPV(+)) oropharyngeal cancer on average have better prognoses, which led to 
recommendations to de-escalate aggressive treatment and limit toxicity for this group, particularly if they 
have a favorable smoking history (5).  Tobacco is a strong risk factor for the development of HNSCC via 
documented cellular, molecular, and epigenetic effects (6-8).   Previous studies have shown that all-cause 
mortality is worse among survivors who continue to smoke compared to never smokers, but this same benefit 
is not seen when comparing patients who recently quit smoking to patients who continue to smoke after 
diagnosis (9).  However, analyzing smoking history is complex (10-12), and studies in lung squamous cell 
carcinoma have indicated that duration of smoking as well as time since quitting is associated with incidence 
(13) and survival (14-16).  
It is essential to better define the association between tobacco use and HNSCC survival and oncologic 
outcomes. This is best derived from prospective, structured smoking assessments to properly understand the 
potential role of smoking in risk stratification treatment models that include other prognostic factors. Smoking 
is associated with lifestyle and health variables, such as alcohol use, BMI and comorbidities. All of these may 
also be associated with clinical outcomes of interest in HNSCC patients.  Thus, there is strong interest in 
examining the risk of tobacco use on long term survival and recurrence rates in HNSCC, particularly  in 
combination with other established prognostic factors.  These data will be instrumental in selecting the 
appropriate cohorts for potential treatment intensification or de-escalation. 
From an epidemiologic perspective, smoking status is frequently stratified into three groups of never, 
current, and former smokers.  However, such a classification  does not fully account for the intensity and 
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duration of tobacco exposure. Intensity is usually defined in terms of cigarettes per day and duration in years 
of use.  Since a long history of high intensity tobacco use is associated with many adverse outcomes, and may 
contribute to carcinogenesis and treatment sensitivity, we hypothesize that separate consideration of recent 
and remote tobacco exposure groups may aid in better understanding the impact of tobacco use on oncologic 
and survival outcomes. 
In this paper we assessed the effects of lifetime cigarette exposure in a prospectively collected, 
unselected populat on of previously untreated, incident HNSCC patients. This cohort of 687 is actively followed 
as part of an epidemiologic study.  The study protocol includes annual questionnaires and extensive quality 
control and completeness checks, and thus constitutes very high quality data on which to study questions 
regarding the potential importance of tobacco and other risk factors on survival and recurrence outcomes.   
 
PATIENTS AND METHODS 
Full details are provided in the online supplementary materials, below is a brief description of the study design, 
the patients and the methods. 
Recruitment.  From November 2008 through July 2013, every previously untreated, incident adult HNSCC patient 
with primary disease evaluated in the Head and Neck Oncology Program of the University of Michigan (UM; Ann Arbor, 
MI) Comprehensive Cancer Center was prospectively screened for eligibility and 92% signed a written informed consent 
and were enrolled.  This unselected study population represented 28% of incident HNSCC cases in the State of Michigan.  
The study was approved by a University of Michigan Institutional Review Board. 
Variable Definitions.  The date of diagnosis was the date the patient was diagnosed with a biopsy confirmed 
squamous cell carcinoma at UM.  Comorbidity was assessed at diagnosis through medical chart review using the Adult 
Comorbidity Evaluation 27 (ACE-27) (17), a validated instrument to grade the severity of comorbidities in patients with 
cancer.  Prior HNSCC was defined as a previous primary tumor in the head and neck more than five years earlier. Self-
reported smoking history was collected at the time of enrollment and included age of initiation, cessation, and smoking 
status, categorized into never, current (including patients who quit within 12 months of diagnosis), or former (quit over 
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12 months prior to diagnosis).  Cigar, pipe, and smokeless tobaccos were frequently missing age of initiation and 
cessation.  There were very few non-cigarette smokers in our cohort who only used pipe or cigar tobacco.  Because it is 
known that the risk of HNSCC is not elevated among ever cigarette smokers who also us cigar and pipe tobaccos (18), 
only cigarette data were further analyzed.  The cumulative quantity of cigarettes smoked in the recent past (less than 10 
years before diagnosis) and at remote times (earlier than 10 years before diagnosis) were considered.  These cumulative 
amounts were calculated by multiplying the intensity of use (pack years) by the duration of use during each period, as 
shown in Supplementary Figure 1.  Duration of use was determined by the cigarette initiation and cessation dates.  
Follow-up.  Patients were followed at NCCN guideline intervals for routine cancer care and surveillance.  Tumor status 
(recurrence, persistent disease, second primary) was updated annually during a medical record review and annual 
surveys.  Deaths were confirmed through the Social Security Death Master File, yearly surveys, family notification, and 
medical record reviews.  Survival time was censored to 2/1/14 or the last known contact date for subjects lost to follow-
up.  Tumor status was censored to the last date of each subject’s annual medical record review(19); the last data 
observation occurred in September 2014.  Deaths due to other causes were censored at date of death for disease 
specific survival time (DST). Study Population.  The study population of 687 subjects was comprised of patients mainly 
with oral cavity and oropharynx primary sites (39% and 37%, respectively) and Stage IV (59%) disease (Table 1).  The 
mean age at diagnosis was 61 years (SD: 12 years).  Among all smokers, the mean age of initiation was 24 years (SD: 10 
years); among former smokers, the mean age of cessation was 46 years (SD: 15 years).  Treatment modalities included 
surgery alone (25%) or surgery with adjuvant radiation or chemoradiation (20%), chemoradiation alone (40%), radiation 
alone (7%), or palliative/unknown (8%) treatment.  Ten percent of patients were never rendered disease free after 
treatment.  Recurrence patterns were local only (25%), regional ± locoregional (36%), and distant ± locoregional (39%).  
Median follow-up for overall survival was 30 months and the estimated two year overall survival rate was 78%.  Median 
follow-up for recurrence-free time was 24 months and the estimated two year recurrence- free rate was 75%.   
HPV Status.  HPV status was determined from biopsy or surgical resection formalin-fixed, paraffin-embedded 
blocks for 362 subjects using previously reported and validated PCR methods (20).  HPV status was unable to be 
determined for 325 subjects.  Subjects with equivocal or missing HPV status were included in study and given an HPV 
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status of “unknown”.  Among subjects with adequate DNA or tissue specimens, 84% of oropharynx cancers were HPV(+), 
12% of oral cavity, 13% of larynx, and 25% of hypopharynx.   
Statistical Analysis.  Chi-square testing and analysis of variance assessed differences in clinical and 
epidemiological characteristics with tobacco use. The Kaplan-Meier method was used to estimate rates and graphically 
visualize overall survival (OST), recurrence-free (RFT), and disease specific survival (DST) time. Time-to-event outcomes 
were defined from diagnosis to death any cause (OST), time to disease recurrence (RFT), or time to death from HNSCC 
malignancy. forFor patients with persistent disease, time to recurrence was defined as one day.     
Single variable and multivariable Cox proportional hazard models were used to test associations between clinical 
and epidemiological variables with OST, RFT, and DST.  Covariates included were age, gender, marital status, history of 
prior HNSCC or other cancer, stage, tumor site, comorbidity score, BMI, HPV status, alcohol, and tobacco use.  
Differences in outcome by planned treatment were explored, though ultimately eliminated from the final multivariable 
models because of the high collinearity observed between disease site and treatment plan.  The multivariable analysis 
excluded 4 subjects missing BMI information, resulting in a total of 683 subjects for analysis. HPV status was defined in 
three groups; positive, negative and unknown. To address potential bias introduced by creating a category for missing 
HPV status, sensitivity analyses were performed using multiple imputation and inverse probability weighting.  The 
results from this are shown in the online supplementary materials section. A post-hoc subset analysis was also 
performed analyzing HPV(+) and HPV(-) cancers separately. 
 
RESULTS 
Univariate Clinical and Demographic Effects on Outcome: Clinical variables associated with worse 
OST, RFT, and DST included increasing patient age, single marital status, history of prior HNSCC (> 5 years 
previously), tumor stage, disease site, comorbidity score, lower BMI, and HPV negative status (Table 1).  We 
noted a 3-5% decrease in relative risk per year for every one unit increase in BMI.  One of the strongest 
predictors of all measures of relapse and survival was comorbidity score, with a clear trend by extent of 
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comorbidities.  The effect of age and comorbidities were strongest for OST, whereas the effects of stage and 
prior HNSCC were strongest for DST. 
Univariate Smoking Effects on Outcome: Cigarette use (never, current, former) was significantly 
associated with an increased risk of death from all causes and disease-specific death.  Never smoking was 
associated with improved overall (Figure 1A), relapse-free (Figure 1B), and disease-specific survival (Figure 1C).  
Significantly worse OST, RFT, DST were associated with every 10 year increase in pack years of use (HR (95% 
CI): 1.10 (1.05, 1.15), 1.07 (1.02, 1.12), 1.09 (1.03, 1.16), respectively, Table 1). As expected, smokers of over 
20 pack years had significantly worse outcomes compared to never smokers (Figures 1D – 1F).  When former 
smokers were categorized by year since quitting, there was little separation between quitting within 10 years 
or quitting more than 10 years before diagnosis in OST, RFT, or DST (Figures 1G – 1I), although all outcomes 
were consistently worse in smokers compared to nonsmokers.     
Recent Tobacco Use Compared to Remote Use: To better understand the influence of cigarette 
smoking on outcome measures, smoking history was separated into recent and remote use, derived from the 
patient’s age at initiation, years of duration, and intensity.  Graphically, we observed that the amount of 
remote cigarette use among smokers (accumulated up to 10 years prior to diagnosis) was associated with 
worse survival and recurrence free times (Figure 2A-2C). Although current cigarette use appeared associated 
with worse survival and recurrence free times when compared to never smokers, the amount of recent 
cigarette use (accumulated within 10 years of diagnosis) was not (Figure 2D-2F). Among smokers, differences 
in outcome (HR (95% CI) per 10 pack years) by intensity of remote use were significant for worse OST, RFT and 
for DST survival (1.11 (1.04, 1.18), 1.09 (1.02, 1.17), and 1.11 (1.02, 1.20), respectively).  Among recent users, 
no evidence of meaningful differences in outcome by intensity of recent use were found as evidenced in 
graphical representation and the fact that the hazard ratios for each outcome were wide and contained 1.00  
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(HR (95% CI) per 10 pack years for OST, RFT, DST: 0.94 (0.68, 1.30), 1.05 (0.75, 1.46), 0.98 (0.64, 1.49), 
respectively).  
Multivariable Clinical, Demographic and Smoking Effects on Outcome:  In multivariable analysis, 
history of prior HNSCC, tumor stage, comorbidity score and HPV status remained significant prognostic factors 
for all outcome measures while smoking history was no longer statistically significant in the risk-adjusted 
models (Table 2).  Age and BMI remained statistically significant for overall survival.  Interestingly, pack years 
of use among cigarette smokers was not significantly associated with the outcome measures after adjustment 
for confounding clinical factors.  Sensitivity analyses did not suggest any changes to the conclusions reported 
after applying alternative strategies for missing HPV data (Supplementary materials, Table 1).  
In multivariable analysis, remote (> than 10 years prior to diagnosis) cigarette use was not a significant 
prognostic variable after adjustment for other prognostic factors (HR (95% CI) per 10 pack years: 1.03 
(0.95,1.12), 1.05 (0.97,1.15), 1.08 (0.97,1.20), respectively for OST, RFT, DST). 
Tobacco Use, HPV status and Outcome: In HPV(+) patients, for overall (Figure 3A), recurrence-free 
(Figure 3B), and disease-specific survival (Figure 3C), nonsmokers showed marginal improvements in survival 
compared to smokers.  Outcomes were better for HPV(+) patients compared to  all HPV(-) patients, regardless 
of smoking history.  In univariate analysis, HPV(+) nonsmokers had better outcomes compared to HPV(+) 
smokers though only OST reached statistical significance (HR (95% CI): 0.22 (0.05, 0.94), 0.36 (0.12, 1.08), 0.16 
(0.02, 1.20) for OST, RFT, DST respectively).  In multivariable analysis, HPV(+) nonsmokers compared to HPV(+) 
smokers had improvements in outcome that did not achieve statistical significance (HR (95% CI): 0.22 (0.05, 
1.04), 0.34 (0.11, 1.06), 0.15 (0.02, 1.31) for OST, RFT, DST respectively), after adjustment for confounding 
factors.   
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In HPV(-) patients, there was little survival difference between nonsmokers and smokers for overall 
(Figure 3A), recurrence-free (Figure 3B), and disease-specific survival (Figure 3C)..  In univariate analysis, HPV(-
) nonsmokers showed marginal improvements in overall survival compared to HPV(-) smokers (HR (95% CI): 
0.88 (0.48, 1.59)).  For recurrence-free and disease-specific survival in HPV(-) patients, never smoking status 
showed no significant improvements in survivorship compared to patients with a history of ever smoking (HR 
(95% CI): 1.21(0.68, 2.14), 0.97 (0.47, 2.00)) for RFT and DST respectively.  In multivariable analysis, among 
patients with HPV(-) disease, OST, RFT, and DST were not significantly associated with never or ever smokers 
(HR (95% CI): 1.45 (0.72, 2.94), 1.62 (0.82, 3.19), 1.52 (0.65, 3.55)) respectively, after adjustment for 
confounding factors.  
Association of Tobacco Use and Clinical Variables: Smoking status (never, current, former) was 
strongly associated with comorbidity score, age, tumor site, BMI, and HPV status, all of which were 
significantly associated with outcomes (Table 3). Among subjects with a smoking history, cigarette pack years, 
both recent and remote were significantly associated with age and disease site (Table 4). Increased 
comorbidity score was significantly associated with pack years among smokers (Table 4; p<.001) with a clear 
monotonic trend (Figure 4A).  When taking into account duration and intensity of smoking, remote cigarette 
use (Figure 4B; p<.0001) was more strongly associated with severity of comorbidity score than recent cigarette 
use (Figure 4C; p=0.88).   
DISCUSSION 
In this large, prospective cohort of HNSCC patients, we have confirmed the simple association of 
cigarette use with overall survival (21, 22).  When considering only smoking status, never smokers were 
consistently identified as a prognostically favorable patient group for OST, RFT, and DST survival.  Similarly, 
pack years showed a modest increased hazard of death for every 10 pack years of use in univariate analysis.  
However, in multivariable analysis, we found that both smoking status and pack years were not significant 
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after adjustment for other clinical factors including medical comorbidities, history of prior HNSCC, and BMI.  
When former smokers were grouped by year since quitting, there was not significant separation in OST, RFT, 
or DST curves. This study demonstrates that a more refined consideration of cigarette use based upon timing 
and intensity may be useful when considering HNSCC outcomes. In particular, cigarette use at earlier times 
may be more clinically relevant than is more recent cigarette use.     
Our data also demonstrate that comorbidities are highly related to pack years, particularly with remote 
use, in bivariate analysis.  The univariate effect of remote cigarette use diminishes in multivariate analyses, 
and comorbidities have a strong effect on outcome, particularly on overall survival. Since tobacco use is a 
likely contributing factor to these comorbidities, it is possible that some of the negative impact of smoking on 
outcomes in HNSCC patients is mediated through comorbidities. These findings could have potential 
implications on the use of smoking history in risk stratification for patients with HNSCC (5, 23-25).  It is likely 
that a more refined approach considering temporal smoking habits along with comorbidities would afford a 
more predictive model. 
Remote cigarette use was significantly associated with outcomes, history of prior HNSCC, and 
comorbidities whereas recent use was not.  Greater pack years were associated in an increasing monotonic 
trend with more severe comorbidity.  We hypothesize that patients who initiated intense smoking for a long 
duration spanning their lifetime may accumulate more somatic mutations (7, 26-28) than patients who 
smoked less or more recently, and the implications from a carcinogenesis standpoint merit further study.  
Lifetime smoking had a significant impact on OST, and this could be phenotypically associated with increased 
smoking related comorbidities such as cardiovascular and pulmonary disease, contributing to a poorer survival 
chance after cancer treatment.  Comorbidities at diagnosis have been correlated with survival (29) and have 
been externally validated as an independent predictor of survival in a prognostic HNSCC model (30).  In 
another study, a model of comorbidities, clinical, and pathological information predicted survival better than 
pathological TNM staging (31).  Management of comorbidities at diagnosis may be a key factor for improving 
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survival rates in HNSCC patients.  Survivors who continue smoking compared to patients who never smoked 
are at higher risk of a recurrence or second primary (32).  Perhaps continued tobacco exposure exacerbates 
medical comorbidities in a manner that replicates the biology and medical condition of remote smokers.  
Further understanding of the  biological and clinical impact of smoking during treatment is required (33).   
Our data did not demonstrate alcohol use as a prognostic factor, even in univariate analyses, in 
contrast to other studies which found alcohol use as a strong prognostic factor for HNSCC patients (34, 35).  In 
multivariable and b variate analyses, increased BMI was associated with both longer survival and less tobacco 
use.  Low BMI, as a measure of nutritional status, was prospectively associated with increased risk of HNSCC 
mortality among smokers (36), increased risk of death during chemoradiation (37), and a negative prognostic 
factor post-treatment (38).  Other studies found obesity to be adversely associated with disease-specific 
survival in patients with tongue cancer (39).  Smoking and BMI are likely related through the various metabolic 
effects of smoking on cell physiology, modification of dietary habits related to smoking (40), hormonal effects 
mediated by nicotine (41), and via other confounders (42).    
Subjects with HPV(+) disease, had better OST than HPV(-) subjects, regardless of smoking history.  In 
HPV(+) patients, smoking history was only marginally significant and was no longer significantly associated 
with survival outcomes after adjusting for other prognostic factors.  In multivariable analysis, HPV(-) 
nonsmokers and ever smokers did not have significantly different OST, RFT, DST.  It is an important and unique 
finding that HPV(-) nonsmokers did not fare noticeably better.  For tumor recurrence, other factors including 
stage, comorbidity score, and history of prior HNSCC had stronger and more consistent associations.  Although 
previous studies that reported a strong association between survival, extent of tobacco use and HPV status (5, 
23, 43) these studies relied on highly selected clinical trial data, which have strong selection bias for patients 
with low comorbidity and may have incomplete smoking histories. In contrast, our detailed smoking history 
was obtained through self-reported surveys in an unselected prospectively collected cohort. Our contrasting 
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results could also be partly due to the contemporary epidemiologic shift of HPV related oropharyngeal cancer 
with increasing numbers of non-smokers over the last two decades (44-46).   
This study analyzed the associations of cigarette use with oncologic and survival outcomes in head and 
neck cancer in a large, carefully studied prospective cohort.  Smoking status was consistently correlated with 
worse oncologic and survival outcomes across our univariate analyses.  In multivariable analyses we identified 
high comorbidity score, history of prior HNSCC, negative HPV status, increasing cancer stage and low BMI as 
highly significant characteristics that negatively affect OST, RFT and DST. However, in our patient population, 
smoking history was not an independent prognostic factor after adjusting for these other significant 
covariates.  Our findings suggest that continued efforts at identifying and understanding the interactions of 
smoking and other health behaviors with other patient characteristics will be important in developing new 
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Table 1. Univariate Cox proportional hazards model for survival outcome 
 
    OST RFT DST 
   
No. of 
Patients HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
 Age at Dx 10 years 687 1.44 (1.26, 1.64) <0.0001 1.26 (1.10, 1.43) 0.0007 1.21 (1.02, 1.43) 0.03 
 Genderb Male (ref) 504 (ref)  (ref)  (ref)  
  Female 183 1.31 (0.94, 1.83) 0.11 1.13 (0.80, 1.60) 0.48 1.21 (0.78, 1.86) 0.39 
 Married Married 436 0.55 (0.40, 0.74) 0.0001 0.65 (0.48, 0.89) 0.007 0.66 (0.44, 0.98) 0.04 
  Not Marrieda  251 (ref)  (ref)  (ref)  
 Prior Cab  108 1.04 (0.69, 1.57) 0.86 0.86 (0.55, 1.34) 0.51 0.85 (0.48, 1.50) 0.58 
 
Prior 
HNSCCc  31 2.83 (1.60, 5.02) 0.0004 3.10 (1.81, 5.30) <0.0001 3.25 (1.63, 6.49) 0.0008 
 Ca Stage I/Cis (ref) 108 (ref)  (ref)  (ref)  
  II 79 3.24 (1.32, 7.95) 0.01 1.47 (0.58, 3.70) 0.41 2.50 (0.60, 10.47) 0.21 
  III 97 4.14 (1.78, 9.61) 0.0009 3.04 (1.41, 6.57) 0.005 5.66 (1.63, 19.69) 0.006 
  IV 403 4.90 (2.28, 10.50) <0.0001 3.98 (2.02, 7.84) <0.0001 7.64 (2.41, 24.21) 0.0005 
 
Disease 
Site oral cavity (ref) 271 (ref)  (ref)  (ref)  
  hypopharynx 24 1.60 (0.80, 3.18) 0.19 1.97 (1.01, 3.82) 0.05 1.91 (0.81, 4.49) 0.14 
  larynx 135 0.69 (0.45, 1.05) 0.08 0.80 (0.52, 1.22) 0.30 0.90 (0.54, 1.51) 0.69 
  oropharynx 257 0.58 (0.40, 0.83) 0.003 0.74 (0.51, 1.06) 0.10 0.64 (0.40, 1.03) 0.07 
 
ACE  
comorbidity none (ref) 183 (ref)  (ref)  (ref)  
  mild 322 2.29 (1.44, 3.63) 0.0005 1.64 (1.07, 2.52) 0.02 1.71 (1.00, 2.95) 0.05 
  moderate 125 2.66 (1.58, 4.47) 0.0002 1.96 (1.20, 3.21) 0.007 1.93 (1.03, 3.63) 0.04 
  severe 57 3.99 (2.20, 7.22) <0.0001 2.61 (1.46, 4.65) 0.001 3.13 (1.53, 6.40) 0.002 
 BMI 1 unit increase 683 0.95 (0.92 ,0.98) 0.001 0.97 (0.94, 0.99) 0.02 0.95 (0.92 ,0.99) 0.01 
 HPV status HPV- (ref) 222 (ref)  (ref)  (ref)  
  HPV+ 140 0.39 (0.24, 0.64) 0.0002 0.48 (0.30, 0.78) 0.003 0.42 (0.23, 0.77) 0.005 
  Unknown 325 0.91 (0.65, 1.26) 0.56 0.89 (0.64, 1.25) 0.51 0.79 (0.52, 1.22) 0.29 
 
Alcohol 
Use never (ref) 67 (ref)  (ref)  (ref)  
  current 450 0.75 (0.45, 1.26) 0.27 0.66 (0.40, 1.07) 0.09 0.72 (0.38, 1.38) 0.33 
  former 170 1.11 (0.64, 1.92) 0.72 0.88 (0.52, 1.51) 0.65 1.01 (0.51, 2.02) 0.97 
 
Cigarette 
Use never (ref) 184 (ref)  (ref)  (ref)  
  current  282 2.07 (1.32, 3.25) 0.002 1.31 (0.87, 1.98) 0.20 1.87 (1.05, 3.31) 0.03 
  former 221 2.11 (1.33, 3.36) 0.002 1.51 (0.99, 2.30) 0.06 2.18 (1.22, 3.90) 0.008 
 Pack Years 10 unit increase 687 1.10 (1.05, 1.15) <0.0001 1.07 (1.02, 1.12) 0.007 1.09 (1.03, 1.16) 0.005 
 Years Quit never smoker 184 0.48 (0.31, 0.76) 0.002 0.77 (0.51, 1.16) 0.21 0.53 (0.30, 0.94) 0.03 
  quit 10+ years 158 0.93 (0.64, 1.37) 0.73 1.09 (0.74, 1.62) 0.67 1.13 (0.70, 1.82) 0.61 
  quit <10 years 59 1.26 (0.77, 2.06) 0.36 1.33 (0.79, 2.23) 0.29 1.20 (0.62, 2.32) 0.60 
  current smoker 279 (ref)  (ref)  (ref)  
 
Remote 
Pack Years 10 unit increase 680 1.13 (1.07, 1.19) <0.0001 1.09 (1.03, 1.16) 0.004 1.12 (1.04, 1.20) 0.002 
 
Recent 
Pack Years 10 unit increase 680 1.20 (0.98, 1.64) 0.07 1.10 (0.89, 1.36) 0.40 1.12 (0.86, 1.46) 0.38 
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Table 1 Abbreviations: OST=Overall Survival Time, RFT=Recurrence-Free Time, DST=Disease Specific Survival Time, No.=Number, HR=Hazard Ratio, 
CI=Confidence Interval, HNSCC=Head and Neck Squamous Cell Cancer,   Cis=insitu, ACE=Adult Comorbidity Evaluation-27 summary score, 
BMI=Body Mass Index, HPV= Human papillomavirus 
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Table 2. Multivariable Cox proportional hazards model for survival outcomes.  
 
   OST RFT DST 
  
No. of 
Patients HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Age 10 years unit 683 1.30 (1.12, 1.51) 0.0005 1.16 (1.00, 1.35) 0.05 1.12 (0.93, 1.36) 0.24 
Gender Male 500 (ref)  (ref)  (ref)  
 Female 183 1.07 (0.74, 1.54) 0.73 0.95 (0.65, 1.39) 0.79 1.08 (0.68, 1.73) 0.74 
Married Married 434 0.77 (0.55, 1.09) 0.14 0.78 (0.55, 1.10) 0.15 0.90 (0.58, 1.39) 0.63 
 Not Married  249 (ref)  (ref)  (ref)  
Prior Cancer  108 0.83 (0.53, 1.30) 0.41 0.73 (0.46, 1.16) 0.18 0.67 (0.37, 1.23) 0.20 
Prior HNSCC  31 2.31 (1.25, 4.26) 0.008 2.73 (1.54, 4.84) 0.0006 2.77 (1.31, 5.87) 0.008 
Ca Stage I/Cis 107 (ref)  (ref)  (ref)  
 II 78 3.24 (1.31, 8.02) 0.01 1.40 (0.55, 3.54) 0.48 2.37 (0.56, 9.97) 0.24 
 III 97 5.02 (2.14, 11.80) 0.0002 3.34 (1.53, 7.31) 0.003 6.58 (1.87, 23.19) 0.003 
 IV 401 7.20 (3.29, 15.73) <0.0001 5.03 (2.50, 10.11) <0.0001 10.54 (3.26, 34.05) <0.0001 
Disease Site Oral Cavity 269 (ref)  (ref)  (ref)  
 Hypopharynx 23 0.76 (0.35, 1.66) 0.50 1.11 (0.53, 2.33) 0.79 0.92 (0.37, 2.31) 0.86 
 Larynx 135 0.52 (0.33, 0.82) 0.005 0.66 (0.42, 1.04) 0.08 0.62 (0.35, 1.08) 0.09 
 Oropharynx 256 0.72 (0.47, 1.11) 0.14 0.81 (0.52, 1.25) 0.33 0.72 (0.41, 1.26) 0.25 
ACE 
comorbidity none 182 (ref)  (ref)  (ref)  
 mild 320 1.63 (1.00, 2.67) 0.05 1.27 (0.81, 2.01) 0.30 1.35 (0.75, 2.41) 0.31 
 moderate 125 2.66 (1.58, 4.47) 0.003 1.69 (1.00, 2.87) 0.05 1.81 (0.92, 3.54) 0.08 
 severe 56 2.69 (1.38, 5.25) 0.004 1.95 (1.01, 3.78) 0.05 2.72 (1.21, 6.12) 0.02 
BMI 1 unit increase 683 0.96 (0.93, 0.99) 0.01 0.98 (0.95, 1.00) 0.09 0.97 (0.93, 1.00) 0.06 
HPV status HPV-  221 (ref)  (ref)  (ref)  
 HPV+ 140 0.41 (0.22, 0.73) 0.003 0.48 (0.27, 0.84) 0.01 0.37 (0.17, 0.77) 0.008 
 Unknown 322 0.83 (0.58, 1.20) 0.32 0.79 (0.55, 1.15) 0.22 0.73 (0.46, 1.17) 0.20 
Alcohol Use never 66 (ref)  (ref)  (ref)  
 current 448 1.21 (0.68, 2.15) 0.51 0.86 (0.50, 1.49) 0.60 0.96 (0.48, 1.92) 0.90 
 former 169 1.16 (0.64, 2.12) 0.62 0.90 (0.51, 1.61) 0.72 0.99 (0.47, 2.07) 0.98 
Cigarette Use never  183 0.76 (0.45, 1.28) 0.30 0.95 (0.59, 1.53) 0.83 0.81 (0.42, 1.54) 0.81 
Pack Years 10 unit increase 683 1.05 (0.99, 1.11) 0.13 1.05 (0.98, 1.12) 0.14 1.04 (0.96, 1.13) 0.33 
 
Table 2 Abbreviations:  
No.=Number, OST=Overall Survival Time, RFT=Recurrence-Free Time, DST=Disease Specific Survival Time, HR=Hazard Ratio, CI=Confidence 
Interval, HNSCC=Head and Neck Squamous Cell Cancer,   Cis=insitu, ACE=Adult Comorbidity Evaluation-27 summary score, BMI=Body Mass 
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Table 3. Association of Smoking Status with clinical and epidemiologic characteristics 
Variable Subgroup No. of Patients 
% of Patients  
Never Smokers 
% of Patients 
Current Smokers 





Age Category <60 345 30 50 21 <0.001 
 
60-75 246 20 39 41  
 
>75 96 35 14 51  
Gender Male 504 26 41 33 0.55 
 
Female 183 28 43 29  
Married Married 251 18 56 26 <0.001 
 
Not Married 436 32 33 36  
Prior Cancer No 579 27 42 31 0.48 
 
Yes 108 26 37 37  
Prior HNSCC No 656 27 42 31 0.07 
 
Yes 31 29 23 48  
Stage I/Cis 108 28 42 31 0.37 
 
II 79 28 41 32  
 
III 97 16 48 35  
 
IV 403 29 39 32  
Disease Site Larynx 135 4 66 30 <0.001 
 
Oral Cavity 271 29 41 30  
 
Oropharynx 257 37 27 35  
 
Hypopharynx 24 17 46 38  
ACE comorbidity none 183 40 36 24 <0.001 
 
mild 322 23 43 34  
 
moderate 125 19 44 37  
 
severe 57 19 42 39  
BMI category underweight (<18.5) 33 3 76 21 <0.001 
 
normal weight (18.5-24.9) 233 19 54 27  
 
overweight (25-29.9) 238 30 30 40  
 
obese (30+) 179 37 33 30  
HPV HPV-  222 20 50 30 0.001 
 
HPV+ 140 37 31 31  
 
Unknown 325 27 39 34  
Alcohol Use never 67 48 31 21 <0.001 
 
current 450 29 42 29  
 
former (quit >12 months) 170 13 43 44  
Table 3 Abbreviations:  
No.=Number. %=proportion of patients within subgroup (row).  HNSCC=Head and Neck Squamous Cell Cancer, Cis=insitu, ACE=Adult Comorbidity 
Evaluation-27 summary score, BMI=Body Mass Index, HPV= Human papillomavirus 
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Table 4: Associations of Clinical and Epidemiologic Characteristics with Cumulative Pack Years Remote and Recent 






Pack years p-value 
Mean (std) 
Remote 
Pack Years p-value 
Mean (std) 
Recent 
Pack Years p-value 
Age Category <60 243 30.2 (23.8) <0.001 21.5 (18.5) <0.001 9.1 (7.4) <0.001 
 
60-75 198 40.0 (27.6)  33.4 (23.4)  6.6 (6.8)  
 
>75 62 36.6 (34.4)  34.0 (31.1)  3.2 (5.5)  
Gender Male 372 36.1 (26.5) 0.09 28.8 (22.6) 0.10 7.6 (7.4) 0.23 
 
Female 131 31.4 (28.8)  24.9 (24.2)  6.7 (6.8)  
Married Married 206 38.1 (27.1) 0.03 29.6 (23.4) 0.14 8.9 (7.1) <0.001 
 
Not Married 297 32.6 (27.0)  26.5 (22.9)  6.3 (7.1)  
Prior Ca No 423 34.1 (27.2) 0.18 26.8 (22.7) 0.03 7.6 (7.4) 0.09 
 
Yes 80 38.6 (27.1)  32.9 (24.8)  6.1 (6.3)  
Prior HNCa No 481 34.7 (27.3) 0.48 27.4 (23.0) 0.12 7.5 (7.3) 0.01 
 
Yes 22 38.9 (25.2)  35.3 (24.6)  3.6 (4.7)  
Stage I/Cis 78 35.9 (29.2) 0.47 28.0 (23.9) 0.47 7.9 (7.5) 0.55 
 
II 57 37.6 (25.6)  31.2 (21.1)  7.7 (6.5)  
 
III 81 37.7 (26.9)  29.6 (23.0)  8.1 (7.9)  
 
IV 287 33.3 (27.0)  26.5 (23.3)  7.0 (7.1)  
Disease Site Larynx 129 42.3 (25.0) <0.001 32.9 (20.9) 0.002 9.7 (7.1) <0.001 
 
Oral Cavity 193 36.1 (30.1)  28.6 (25.4)  7.7 (7.2)  
 
Oropharynx 161 27.5 (23.1)  22.6 (20.6)  5.1 (6.8)  
 
Hypopharynx 20 34.9 (27.4)  27.6 (24.7)  6.8 (6.8)  
Comorbidities  none 109 26.3 (22.0) <0.001 19.9 (17.4) <0.001 7.0 (6.7) 0.88 
 
mild 247 35.9 (28.1)  28.5 (23.8)  7.6 (7.4)  
 
moderate 101 37.3 (27.4)  30.0 (22.9)  7.3 (7.5)  
 
severe 46 43.9 (28.3)  37.0 (26.7)  7.0 (6.8)  
BMI category underweight (<18.5) 32 40.5 (31.1) 0.16 31.8 (25.7) 0.34 8.7 (6.9) 0.01 
 
normal weight (18.5-24.9) 188 34.0 (25.0)  26.5 (20.7)  7.9 (7.0)  
 
overweight (25-29.9) 167 32.2 (25.3)  26.6 (22.0)  5.9 (6.5)  
 
obese (30+) 113 38.5 (31.8)  30.4 (27.5)  8.2 (8.3)  
HPV HPV-  175 38.2 (25.4) 0.03 30.2 (21.8) 0.03 8.4 (6.8) 0.07 
 
HPV+ 86 28.7 (28.5)  22.1 (23.9)  6.7 (7.9)  
 
Unknown 235 34.6 (27.7)  28.0 (23.5)  6.8 (7.2)  
Alcohol Use never 35 37.6 (33.0) 0.22 29.3 (27.6) 0.07 8.3 (9.8) 0.44 
 
current 320 33.3 (25.6)  26.0 (21.2)  7.5 (7.1)  
 
former (quit >12 months) 148 37.7 (28.8)  31.3 (25.6)  6.8 (6.8)  
Cigarette Use never        
 
current 282 40.4 (26.9) <0.001 29.0 (22.1) 0.19 11.6 (6.3) <0.001 
 
former (quit >12 months) 221 27.7 (25.9)  26.2 (24.3)  1.9 (4.0)  
Table 4 Abbreviations:  
No.=Number, std=standard deviation, HNSCC=Head and Neck Squamous Cell Cancer, Cis=insitu, ACE=Adult Comorbidity Evaluation-27 summary 
score, BMI=Body Mass Index, HPV= Human papillomavirus 
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Supplemental Table 1. Hazard Ratio (95% Confidence Interval) for selected covariates from multivariable Cox model 

























A=Missing Category. B=Omit subjects with missing HPV. C=Inverse Probability Weighting. D=Multiple Imputation 
  
 
 OST RFT DST 
  Missing Data Strategy HR (95% CI) HR (95% CI) HR (95% CI) 
HPV Status HPV(+) vs. HPV( –) A 0.41 (0.22, 0.73) 0.48 (0.27, 0.84) 0.37 (0.17, 0.77) 
  B 0.40 (0.20, 0.82) 0.36 (0.18, 0.74) 0.30 (0.12, 0.72) 
  C 0.34 (0.16, 0.72) 0.34 (0.16, 0.74) 0.24 (0.09, 0.63) 
  D 0.38 (0.20, 0.72) 0.37 (0.19, 0.72) 0.25 (0.10, 0.63) 
Smoking Status never vs. ever A 0.76 (0.45, 1.28) 0.95 (0.59, 1.53) 0.81 (0.42, 1.54) 
  B 0.93 (0.47, 1.85) 1.04 (0.54, 1.98) 1.01 (0.44, 2.30) 
  C 0.91 (0.43, 1.90) 1.16 (0.58, 2.33) 0.93 (0.37, 2.29) 
  D 0.81 (0.48, 1.36) 1.14 (0.70, 1.87)                                 0.87 (0.45, 1.68) 
Cigarette Pack Years 10 unit increase A 1.05 (0.99, 1.11) 1.05 (0.98, 1.12) 1.04 (0.96, 1.13) 
  B 1.03 (0.95, 1.11) 1.03 (0.95, 1.13) 1.05 (0.94, 1.16) 
  C 1.04 (0.95, 1.13) 1.06 (0.97, 1.16) 1.06 (0.95, 1.18) 
  D 1.05 (0.98, 1.11) 1.05 (0.99, 1.12) 1.05 (0.96, 1.14) 
Age 10 year increase A 1.30 (1.12, 1.51) 1.16 (1.00, 1.35) 1.12 (0.93, 1.36) 
  B 1.50 (1.21, 1.86) 1.24 (0.99, 1.54) 1.22 (0.94, 1.60) 
  C 1.58 (1.25, 1.99) 1.28 (1.01, 1.63) 1.32 (0.98, 1.78) 
  D 1.30 (1.11, 1.51) 1.15 (0.98, 1.34) 1.10 (0.90, 1.33) 
Stage IV vs. I A 7.20 (3.29, 15.73) 5.03 (2.50, 10.11) 10.54 (3.26, 34.05) 
  B 5.20 (2.01, 13.48) 3.22 (1.33, 7.80) 8.15 (1.89, 35.15) 
  C 6.27 (2.14, 18.33) 3.30 (1.28, 8.52) 10.28 (1.81, 58.51) 
  D 7.06 (3.22 (15.46) 5.01 (2.49, 10.08) 10.58 (3.26, 34.28) 
 III vs. I A 5.02 (2.14, 11.80) 3.34 (1.53, 7.31) 6.58 (1.87, 23.19) 
  B 4.58 (1.61, 13.04) 2.62 (0.98, 7.04) 6.84 (1.46, 32.18) 
  C 6.02 (1.85, 19.55) 3.06 (1.06, 8.85) 9.37 (1.49, 58.99) 
  D 4.82 (2.03, 11.45) 3.33 (1.51, 7.33) 6.88 (1.94, 24.38) 
 II vs. I A 3.24 (1.31, 8.02) 1.40 (0.55, 3.54) 2.37 (0.56, 9.97) 
  B 2.42 (0.78, 7.53) 1.01 (0.30, 3.39) 2.04 (0.34, 12.42) 
  C 3.11 (0.90, 10.73) 1.01 (0.28, 3.62) 3.82 (0.54, 26.77) 
  D 3.18 (1.28, 7.90) 1.35 (0.53, 3.42) 2.33 (0.55, 9.85) 
Disease Site OP vs. OC A 0.72 (0.47, 1.11) 0.81 (0.52, 1.25) 0.72 (0.41, 1.26) 
  B 0.93 (0.47, 1.87) 1.26 (0.62, 2.56) 0.99 (0.41, 2.35) 
  C 0.95 (0.45, 2.02) 1.26 (0.58, 2.75) 1.10 (0.43, 2.81) 
  D 0.98 (0.58, 1.66) 1.15 (0.66, 2.03) 1.14 (0.57, 2.29) 
 LA vs. OC A 0.52 (0.33, 0.82) 0.66 (0.42, 1.04) 0.62 (0.35, 1.08) 
  B 0.68 (0.38, 1.20) 0.71 (0.39, 1.30) 0.57 (0.27, 1.17) 
  C 0.60 (0.31, 1.17) 0.71 (0.36, 1.41) 0.51 (0.22, 1.22) 
  D 0.55 (0.34, 0.86) 0.69 (0.43, 1.09) 0.64 (0.36, 1.13) 
 HP vs OC A 0.76 (0.35, 1.66) 1.11 (0.53, 2.33) 0.92 (0.37, 2.31) 
  B 1.63 (0.66, 4.07) 2.67 (1.05, 6.77) 1.66 (0.55, 4.99) 
  C 2.12 (0.87, 5.16) 3.60 (1.42, 9.12) 2.73 (0.98, 7.55) 
  D 0.84 (0.38, 1.85) 1.19 (0.56, 2.52) 1.04 (0.41, 2.66) 
Comorbidities mild vs. none A 1.63 (1.00, 2.67) 1.27 (0.81, 2.01) 1.35 (0.75, 2.41) 
  B 1.63 (0.83, 3.21) 1.24 (0.67, 2.27) 1.74 (0.78, 3.88) 
  C 2.03 (0.95, 4.34) 1.17 (0.60, 2.26) 1.97 (0.80, 4.84) 
  D 1.64 (0.99, 2.70) 1.26 (0.79, 2.02) 1.34 (0.74, 2.43) 
 moderate vs. none A 2.66 (1.58, 4.47) 1.69 (1.00, 2.87) 1.81 (0.92, 3.54) 
  B 2.80 (1.32, 5.94) 1.43 (0.70, 2.93) 2.56 (1.03, 6.35) 
  C 3.23 (1.41, 7.42) 1.43 (0.66, 3.07) 2.76 (1.01, 7.51) 
  D 2.20 (1.24, 3.89) 1.59 (0.92, 2.73) 1.77 (0.89, 3.53) 
 severe vs. none A 2.69 (1.38, 5.25) 1.95 (1.01, 3.78) 2.72 (1.21, 6.12) 
  B 2.98 (1.15, 7.74) 1.81 (0.72, 4.56) 2.45 (0.73, 8.17) 
  C 2.49 (0.83, 7.44) 1.48 (0.54, 4.08) 1.65 (0.41, 6.69) 
  D 2.70 (1.38, 5.30) 1.93 (0.99, 3.75) 2.54 (1.11, 5.79) 
BMI (unit=1) 1 unit increase A 0.96 (0.93 ,0.99) 0.98 (0.95, 1.00) 0.97 (0.93, 1.00) 
  B 0.97 (0.94 ,1.01) 1.00 (0.97, 1.04) 1.00 (0.95, 1.04) 
  C 0.98 (0.94, 1.03) 1.01 (0.97, 1.05) 1.01 (0.96, 1.07) 
  D 0.97 (0.94, 0.99) 0.98 (0.95, 1.01) 0.97 (0.93, 1.01) 
Prior HNSCC yes vs. no A 2.31 (1.25, 4.26) 2.73 (1.54, 4.84) 2.77 (1.31, 5.87) 
  B 3.50 (1.24, 9.89) 3.80 (1.40, 10.27) 4.80 (1.52, 15.09) 
  C 2.72 (1.11, 6.68) 4.09 (1.79, 9.31) 4.04 (1.46, 11.18) 
  D 2.28 (1.19, 4.38) 2.60 (1.42, 4.78) 2.69 (1.19, 6.09) 
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Figure 1. Survival benefits according to smoking status (A-C), pack years (D-F), and years since quit (G-I). 
Panels A, B, C: unadjusted OST, RFT, and DST, respectively, by cigarette use (never,  
former, current). Never smokers showed significantly better survival outcomes than smokers in univariable 
Cox models. Interestingly, there were no significant survival differences between former and current 
smokers.  
Panels D, E, F: unadjusted OST, RFT, and DST, respectively, by pack years (never smoker, smokers 0-20 
pack years, and smokers > 20 pack years). Never smokers had significantly better survival outcomes than 
smokers (OST p-value=0.01 in univariable Cox model). There were apparent differences in each category of 
survival events with a 7-10% increase risk of outcome for every 10 pack year increase in cigarette use (Cox 
Proportional models for OST, RFT, DST; p=0.01, 0.007, 0.005, respectively).  
Panels G, H, I: unadjusted OST, RFT, and DST, respectively, by years since quitting (never smoker, smoker 
quit 10+ years ago, smoker quit 0-10 years ago). When grouped by year since quitting, there were no 
significant differences comparing remote and quitters.  
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Figure 2. Association of remote or recent pack years with survival. A, B, C, unadjusted OST, RFT, DST, 
respectively, for pack years comparing never smokers to 0-20 pack years and >20 pack years for remote 
use smokers. For remote use, significant differences in OST favored light pack years compared to heavy 
pack years while RFT and DST were more similar among light and never smokers. D, E, F, unadjusted OST, 
RFT, DST, respectively, for pack years comparing never  
smokers to 0-20 pack years and >20 pack years for recent use smokers. For recent use, moderate 
differences in survival were only observed in RFT comparing light to heavy cigarette use.  
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Figure 3. Survival benefits according to HPV status by smoking history. A, B, C: unadjusted OST, RFT, DST, 
respectively, for HPV status by smoking history (HPV negative nonsmoker (n=44), HPV negative smoker 
(n=178), HPV positive nonsmoker (n=52), HPV positive smoker (n=88)). Differences in outcomes for HPV 
positive patients were evident in univariate analysis according to smoking history; however, outcomes for 
HPV negative patients were similar comparing nonsmokers and ever smokers.  
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Figure 4. Pack years and comorbidity score boxplots among ever smokers. A, Overall pack years differ by 
comorbidity score (none, mild, moderate, severe) with an ANOVA test p-value=0.0006. B, Remote use pack 
years also differ by comorbidity (none, mild, moderate, severe) with an ANOVA test p-value=0.0001. C, 
Recent use pack years did not differ significantly by comorbidity score (none, mild, moderate, severe) with 
an ANOVA test p-value=0.88. Comorbidities were associated with pack years in a monotonic trend when 
accounting for the intensity and duration of smoking habit.  
203x76mm (300 x 300 DPI)  
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ONLINE SUPPLEMENTARY METHODS 
Recruitment.  The University of Michigan’s Head and Neck Specialized Program of Research Excellence (SPORE) 
approached every previously untreated adult HNSCC patient evaluated in the Head and Neck Oncology Program of the 
University of Michigan (UM; Ann Arbor, MI) Comprehensive Cancer Center for participation in our longitudinal 
epidemiology study. The inclusion criterion was a new primary squamous cell carcinoma of the upper aerodigestive 
tract.  Patients with a previous diagnosis of HNSCC within the last 5 years were excluded. Patients with cutaneous 
squamous cell carcinoma of the head and neck, and cervical esophagus were not included. From November 2008 
through July 2013, patients were prospectively screened for eligibility and 92% signed a written informed consent to 
participate.  This unselected study population represented the 28% of incident HNSCC cases in the State of Michigan 
treated at UM.  After consent, subjects completed questionnaires to capture demographics, epidemiologic 
characteristics, behavior modules, and dietary intake.  Subjects completed the questionnaires annually for five years 
after diagnosis and completed dietary intake surveys annually for two years after diagnosis.  Comprehensive smoking 
status data were collected including types of tobacco used, age of initiation, duration and frequency of use, age of 
initiation and cessation, and second hand smoke exposure.  For the 30% of subjects who did not complete the baseline 
health survey, we attempted to abstract the information from the medical record.  This study was approved by the 
Institutional Review Board of the University of Michigan Medical School. 
Variable Definitions. The date of diagnosis was the date the patient was diagnosed with a biopsy confirmed 
squamous cell carcinoma at the University of Michigan.  Comorbidity was assessed using the Adult Comorbidity 
Evaluation 27 (ACE-27) which is a validated score assessing comorbidities in cancer patients [1].  Prior HNCa was defined 
as a previous primary head and neck tumor more than five years earlier. Median household income was collected from 
the 2000 Census and rounded to the nearest dollar; subjects without a valid U.S. postal address for identification in a 
census block were not included in the median household income calculation.  Self-reported smoking history included 
age of initiation, cessation, and smoking status in categories never, current (or quit within 12 months of diagnosis), or 
former (quit over 12 months prior to diagnosis).  Tobacco intensity was characterized by a combination of duration and 
pack years in proximity to an index date defined a number of years prior to diagnosis.  Patient outcomes were analyzed 
based on index dates for cumulative tobacco use up to 5 years prior to diagnosis of cancer, 10 years prior to diagnosis 
and 20 years prior diagnosis.  Supplemental Figure 1 illustrates how pack years were split into two quantities to 
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delineate remote and recent cigarette use based on the patient date of diagnosis, an index date of 10 years prior to 
diagnosis, pack years, and cigarette initiation and cessation dates.  Each line begins at the date of initiation and ends at 
patient reported date of cessation or the date of diagnosis for current smokers.  The length of the line indicates duration 
while the width represents intensity.  Quantities are separated into remote and recent based on the index date.  For 
example, patient 1 has quantifiable remote and recent tobacco use.  Patient 2 quit smoking more than 10 years prior to 
diagnosis.  For patient 2, recent use would be quantified as zero but remote use was more intense than patient 1 and 
therefore patient 2 may have a similar, if not higher, quantity for remote use than patient 1.  The recent use for patient 
3 who began smoking less than 10 years prior to diagnosis is less than that of patient 1.  
Follow-up. Patients were followed according to NCCN guideline intervals and tumor status (recurrence, 
persistent disease, second primary) was updated annually during a medical record review.  If subjects did not return to 
UM for surveillance after treatment, self-reported tumor status from yearly surveys and contact with local physicians 
was used.  A subject was lost to follow-up if we lacked updates after contacting the subject’s referring physician(s), 
address, telephone, and emergency contact and was then censored to the last known contact date.  Deaths were 
confirmed through the Social Security Death Master File, yearly surveys, notification from family, and medical record 
reviews.  Overall survival time was censored to 2/1/14 or the last known contact date for subjects with an invalid SSN 
and/or lost to follow-up.  Tumor status was censored to the last date of each subject’s annual medical record review.  
Persistent disease was given a follow-up time of one day for calculation in time to recurrence.  For subjects with 
concurrent HNSCC primaries, the primary tumor of focus was the tumor with which the patient most clearly presented 
symptomology.   
Other Tobacco Use. Lifetime second hand smoke (SHS) exposure in the home or workplace was experienced by 
82% with a mean exposure of 33.0 years (SD: 17.9 years) while SHS exposure in the past seven days was reported by 
28%.  Ever use of marijuana was suspect to reporting bias and was not considered further in analysis.  Former cigarette 
smokers had fewer mean total pack years (mean: 28.4 pack years, SD: 28.3 pack years) than current smokers (mean: 
41.1 pack years, SD: 31.4 pack years).  Smokeless tobacco was a combination of chewing tobacco and snuff use, 
representing the minimum age of initiation, maximum age of cessation, and a sum of duration.  There was little reported 
use of cigar, pipe, or smokeless tobacco use among never cigarette smokers (n=25).  Cigar, pipe, and smokeless tobaccos 
were frequently missing age of initiation and cessation.  With the missing data and knowing a previous analysis noted no 
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increased risk of HNSCC with the added impact of cigar and pipe tobaccos among ever smokers [2], only cigarette data 
was considered for further analysis.  
Study Population. The population was comprised mainly of oral cavity and oropharynx tumor sites (40% and 
37%, respectively) and Stage IV (58%) (Table 1).  The mean age at diagnosis was 61.1 years (SD: 12.0 years).  Among all 
smokers, the mean age of initiation was 23.7 years (SD: 10.3 years); among former smokers, the mean age of cessation 
was 46.1 years (SD: 14.7 years).  There were 31 subjects diagnosed with a prior HNSCC tumor and 151 subjects 
diagnosed with a prior other cancer prior to HNSCC diagnosis.  The population was mainly males (73%).  Most of the 
population was married (64%) and a significant group of subjects achieved a high school diploma or less education 
(39%).  Household income was $49,287 (SD: $17,891).  BMI included 5% underweight, 34% normal, 35% overweight, and 
26% obese.  All patients were evaluated by our multidisciplinary team and discussed at our tumor board where 
standardized treatment recommendations were made.  Treatment modalities included surgery alone (25%) or surgery 
with adjuvant radiation or chemoradiation (20%), chemoradiation alone (40%), and radiation alone (7%).  A small group 
(8%) received palliative treatment at baseline or their treatment is unknown.  Ten percent of patients were never 
rendered disease free after curative treatment.  Recurrence patterns were local only (25%), regional ± locoregional 
(36%), and distant ± locoregional (39%).  Six percent of subjects developed a second primary in the HN or non-HN region 
after HNSCC diagnosis.  Ten patients had second HNSCC primaries diagnosed concurrently or within one month of their 
date of diagnosis for the primary HNSCC under study; six patients were diagnosed with a HNSCC second primary while 
under follow-up with a median time to diagnosis of 33.2 months.  Median time to non-HNSCC second primary was 9.4 
months.  In men over 60 years of age, there was a 16% prevalence of prostate cancer and an 8% prevalence of colon 
cancer.  The cause of most deaths was attributed to malignancy.  Median follow-up for overall survival (using the Kaplan-
Meier method) was 30 months and the two year overall survival rate estimate was 78%.  Among all living patients, 
median follow-up was 24.4 months.  Median follow-up for recurrence free time was 24 months and the two year 
estimate of the proportion recurrence-free was 74%. 
HPV Status. HPV status was determined from biopsy or surgical resection formalin-fixed, paraffin-embedded 
blocks for 362 subjects using previously reported PCR methods [3]. HPV status was unable to be determined for 325 
subjects.  Subjects with equivocal or missing HPV status were included in analysis and given an HPV status of 
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“unknown”.  Among subjects with adequate DNA or tissue specimens, 84% of oropharynx cancers were HPV(+), 12% of 
oral cavity, 13% of larynx, and 25% of hypopharynx.   
Statistical Analysis.  Chi-square tests were performed to test differences in clinical and epidemiological 
characteristics by smoking status (never, current, former).  Differences in tobacco use intensity variables by 
characteristics were tested with analysis of variance (ANOVA). 
The Kaplan-Meier method was used to estimate rates and graphically visualize overall survival (OST), recurrence-
free (RFT), and disease specific survival (DST) time. Time-to-event outcomes were defined from diagnosis to death any 
cause (OST), time to disease recurrence (RFT), or time to death from HNSCC malignancy. For patients with persistent 
disease, time to recurrence was defined as one day.     
The multivariable analysis excluded 4 subjects missing BMI information, resulting in a total of 683 subjects for 
analysis.  In Table 2 in the paper we present multivariable Cox model results in which we categorized HPV status into 
three groups; positive, negative and unknown.  While this method for handling missing HPV data is generally considered 
preferable in terms of less bias and better efficiency than removal of subjects with unknown HPV status, it can induce 
some bias in the estimates.  As a sensitivity analysis we undertook alternative analyses, based on statistically justified 
approaches, to handle the missing data.  One method is inverse probability weighted Cox model analysis applied to the 
n=361 patients without any missing data.  The weight for each subject is 1/Prob(not missing), where Prob(not missing) is 
derived from a logistic regression model including age, stage, disease site, year of diagnosis, history of cancer, sex, 
marital status, comorbidity score and BMI as predictors.  The second method is multiple imputation followed by Cox 
model analyses of the n=687 subjects.  The imputed values of HPV were created by the method described in Bartlett et 
al [4]. 
Supplemental Table 1 shows the 95% confidence intervals from the multivariable Cox model results for the three 
endpoints of OST, RFT and DST.  We show four sets of results for each endpoint: (a) the results from Table 2 in the 
paper, (b) the results from the Cox model applied to the n=361 subjects without any adjustment for missing data, (c) the 
results from the inverse probability weighted Cox model applied to n=361 subjects and (d) the results after multiple 
imputation.  The results show similar, but not identical confidence intervals, however for nearly all factors and for all 
endpoints there was considerable overlap in the confidence intervals.  The strong and clear associations of the 
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endpoints with stage, age, history of prior HNSCC, comorbidities and HPV status are consistent across analyses.  The 
generally modest and not statistically significant effects of smoking after multivariable adjustment are also replicated. 
All statistical analyses were conducted using SAS software, Version 9.3 of the SAS System for Windows. 
Copyright © 2002-2012 by SAS Institute Inc., Cary, NC, USA. Figures were created in R 3.0.3. 
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Supplemental Table 1. Hazard Ratio (95% Confidence Interval) for selected covariates from multivariable Cox model 
analyses with different strategies for missing HPV status. A=Missing Category. B=Omit subjects with missing HPV. 




























 OST RFT DST 
   HR (95% CI) HR (95% CI) HR (95% CI) 
HPV Status HPV(+) vs. HPV( –) A 0.41 (0.22, 0.73) 0.48 (0.27, 0.84) 0.37 (0.17, 0.77) 
  B 0.40 (0.20, 0.82) 0.36 (0.18, 0.74) 0.30 (0.12, 0.72) 
  C 0.34 (0.16, 0.72) 0.34 (0.16, 0.74) 0.24 (0.09, 0.63) 
  D 0.38 (0.20, 0.72) 0.37 (0.19, 0.72) 0.25 (0.10, 0.63) 
Smoking Status never vs. ever A 0.76 (0.45, 1.28) 0.95 (0.59, 1.53) 0.81 (0.42, 1.54) 
  B 0.93 (0.47, 1.85) 1.04 (0.54, 1.98) 1.01 (0.44, 2.30) 
  C 0.91 (0.43, 1.90) 1.16 (0.58, 2.33) 0.93 (0.37, 2.29) 
  D 0.81 (0.48, 1.36) 1.14 (0.70, 1.87)                                 0.87 (0.45, 1.68) 
Cigarette Packyears 10 unit increase A 1.05 (0.99, 1.11) 1.05 (0.98, 1.12) 1.04 (0.96, 1.13) 
  B 1.03 (0.95, 1.11) 1.03 (0.95, 1.13) 1.05 (0.94, 1.16) 
  C 1.04 (0.95, 1.13) 1.06 (0.97, 1.16) 1.06 (0.95, 1.18) 
  D 1.05 (0.98, 1.11) 1.05 (0.99, 1.12) 1.05 (0.96, 1.14) 
Age 10 year increase A 1.30 (1.12, 1.51) 1.16 (1.00, 1.35) 1.12 (0.93, 1.36) 
  B 1.50 (1.21, 1.86) 1.24 (0.99, 1.54) 1.22 (0.94, 1.60) 
  C 1.58 (1.25, 1.99) 1.28 (1.01, 1.63) 1.32 (0.98, 1.78) 
  D 1.30 (1.11, 1.51) 1.15 (0.98, 1.34) 1.10 (0.90, 1.33) 
Stage IV vs. I A 7.20 (3.29, 15.73) 5.03 (2.50, 10.11) 10.54 (3.26, 34.05) 
  B 5.20 (2.01, 13.48) 3.22 (1.33, 7.80) 8.15 (1.89, 35.15) 
  C 6.27 (2.14, 18.33) 3.30 (1.28, 8.52) 10.28 (1.81, 58.51) 
  D 7.06 (3.22 (15.46) 5.01 (2.49, 10.08) 10.58 (3.26, 34.28) 
 III vs. I A 5.02 (2.14, 11.80) 3.34 (1.53, 7.31) 6.58 (1.87, 23.19) 
  B 4.58 (1.61, 13.04) 2.62 (0.98, 7.04) 6.84 (1.46, 32.18) 
  C 6.02 (1.85, 19.55) 3.06 (1.06, 8.85) 9.37 (1.49, 58.99) 
  D 4.82 (2.03, 11.45) 3.33 (1.51, 7.33) 6.88 (1.94, 24.38) 
 II vs. I A 3.24 (1.31, 8.02) 1.40 (0.55, 3.54) 2.37 (0.56, 9.97) 
  B 2.42 (0.78, 7.53) 1.01 (0.30, 3.39) 2.04 (0.34, 12.42) 
  C 3.11 (0.90, 10.73) 1.01 (0.28, 3.62) 3.82 (0.54, 26.77) 
  D 3.18 (1.28, 7.90) 1.35 (0.53, 3.42) 2.33 (0.55, 9.85) 
Disease Site OP vs. OC A 0.72 (0.47, 1.11) 0.81 (0.52, 1.25) 0.72 (0.41, 1.26) 
  B 0.93 (0.47, 1.87) 1.26 (0.62, 2.56) 0.99 (0.41, 2.35) 
  C 0.95 (0.45, 2.02) 1.26 (0.58, 2.75) 1.10 (0.43, 2.81) 
  D 0.98 (0.58, 1.66) 1.15 (0.66, 2.03) 1.14 (0.57, 2.29) 
 LA vs. OC A 0.52 (0.33, 0.82) 0.66 (0.42, 1.04) 0.62 (0.35, 1.08) 
  B 0.68 (0.38, 1.20) 0.71 (0.39, 1.30) 0.57 (0.27, 1.17) 
  C 0.60 (0.31, 1.17) 0.71 (0.36, 1.41) 0.51 (0.22, 1.22) 
  D 0.55 (0.34, 0.86) 0.69 (0.43, 1.09) 0.64 (0.36, 1.13) 
 HP vs OC A 0.76 (0.35, 1.66) 1.11 (0.53, 2.33) 0.92 (0.37, 2.31) 
  B 1.63 (0.66, 4.07) 2.67 (1.05, 6.77) 1.66 (0.55, 4.99) 
  C 2.12 (0.87, 5.16) 3.60 (1.42, 9.12) 2.73 (0.98, 7.55) 
  D 0.84 (0.38, 1.85) 1.19 (0.56, 2.52) 1.04 (0.41, 2.66) 
Comorbidities mild vs. none A 1.63 (1.00, 2.67) 1.27 (0.81, 2.01) 1.35 (0.75, 2.41) 
  B 1.63 (0.83, 3.21) 1.24 (0.67, 2.27) 1.74 (0.78, 3.88) 
  C 2.03 (0.95, 4.34) 1.17 (0.60, 2.26) 1.97 (0.80, 4.84) 
  D 1.64 (0.99, 2.70) 1.26 (0.79, 2.02) 1.34 (0.74, 2.43) 
 moderate vs. none A 2.66 (1.58, 4.47) 1.69 (1.00, 2.87) 1.81 (0.92, 3.54) 
  B 2.80 (1.32, 5.94) 1.43 (0.70, 2.93) 2.56 (1.03, 6.35) 
  C 3.23 (1.41, 7.42) 1.43 (0.66, 3.07) 2.76 (1.01, 7.51) 
  D 2.20 (1.24, 3.89) 1.59 (0.92, 2.73) 1.77 (0.89, 3.53) 
 severe vs. none A 2.69 (1.38, 5.25) 1.95 (1.01, 3.78) 2.72 (1.21, 6.12) 
  B 2.98 (1.15, 7.74) 1.81 (0.72, 4.56) 2.45 (0.73, 8.17) 
  C 2.49 (0.83, 7.44) 1.48 (0.54, 4.08) 1.65 (0.41, 6.69) 
  D 2.70 (1.38, 5.30) 1.93 (0.99, 3.75) 2.54 (1.11, 5.79) 
BMI (unit=1) 1 unit increase A 0.96 (0.93 ,0.99) 0.98 (0.95, 1.00) 0.97 (0.93, 1.00) 
  B 0.97 (0.94 ,1.01) 1.00 (0.97, 1.04) 1.00 (0.95, 1.04) 
  C 0.98 (0.94, 1.03) 1.01 (0.97, 1.05) 1.01 (0.96, 1.07) 
  D 0.97 (0.94, 0.99) 0.98 (0.95, 1.01) 0.97 (0.93, 1.01) 
Prior HNCa yes vs. no A 2.31 (1.25, 4.26) 2.73 (1.54, 4.84) 2.77 (1.31, 5.87) 
  B 3.50 (1.24, 9.89) 3.80 (1.40, 10.27) 4.80 (1.52, 15.09) 
  C 2.72 (1.11, 6.68) 4.09 (1.79, 9.31) 4.04 (1.46, 11.18) 
  D 2.28 (1.19, 4.38) 2.60 (1.42, 4.78) 2.69 (1.19, 6.09) 
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Supplemental Figure 1. Indexing cumulative tobacco use models by proximity to HNSCC diagnosis. Each line 
begins at he date of initiation and ends at self-reported date of cessation or the date of diagnosis for 
current smokers. The length of the line indicates duration while the width represents intensity. Quantities 
are separated into remote and recent based on the index date.  
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